Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-07-06

Reporting Person: OConnell Daniel Joseph (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-06	Common Stock	C	123	—	Acquired	1542	Direct
2021-07-06	Common Stock	X	35	$4.47	Acquired	1577	Direct
2021-07-06	Common Stock	F	10	$16.00	Disposed	1567	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-06	Series A Preferred Stock	$	C	123	Disposed		Common Stock (123)	Direct
2021-07-06	Warrant (Right to Buy)	$4.47	M	35	Disposed	2025-06-30	Common Stock (35)	Direct

Footnotes

F1: On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F2: On July 6, 2021, the reporting person exercised a warrant to purchase 35 shares of ABOS common stock for $4.47 a share. The reporting person paid the exercise price on a cashless basis, resulting in ABOS's withholding of 10 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 25 shares.